11th Annual · January 2013 · In person
2013
- 25 faculty
- 23 recordings
- 19 slide decks
Symposium
Predicting and Measuring Progression in Early AD
Saturday, January 19, 2013 · 7:00 am - 7:30 pm
- 7:00 - 8:00 amCheck-in and Breakfast
- 8:00 - 8:15Welcome and Introduction
8:15 - 10:45
Mini-Symposium 1
Predictors of Progression to MCI and AD (Epidemiology)
Chair: Mary Ganguli, MD, MPHUniversity of Pittsburgh, Pittsburgh, PA
- New Approaches to Understanding the Relationships of Risk Factors to Cognitive Decline
- The Flynn Effect; How Secular Changes Influence the Predictive Value of Cognitive Performance and the Role of Computer Tomography in Prodromal Dementia in the H70 Study in Gothenburg, Sweden
- Rates and Predictors of Progression from Mild Cognitive Impairment to Dementia: The Mayo Clinic Study of Aging
- Correlates of Conversion to Dementia in a Prospective Community-Ascertained Cohort
- The Fluidity of MCI and the Role of Vascular Biomarkers in Predicting Progression Results from the Indianapolis-Ibadan Study
- Risk Factors for MCI Development and for MCI Progression: Are They The Same?
- 10:45 - 11:00Break
- 11:00 am - 12:00 pm
- 12:00 - 1:00LUNCH
- 1:00 - 2:00Keynote Solving the Dilemma of Treatment Versus Prevention Strategies for Alzheimer’s Disease
2:00 - 4:15
Mini-Symposium 2
Utility of Biomarkers for Predicting and Measuring Progression in Normal Aging, MCI and AD
Chair: Tammie Benzinger, MD, PhDWashington University School of Medicine, St. Louis, MO
- The Cortical Signatures of Alzheimer’s Disease and Frontotemporal Degeneration: Quantitative MRI Biomarkers Detectable prior to Dementia
- Biomarkers, Cognitive Reserve and Cognition in Alzheimer’s Disease
- Neuroimaging for Predicting and Measuring Progression in Preclinical Autosomal Dominant Alzheimer’s Disease
- MRI, FDG-PET and EEG for Predicting Progression in Aging, MCI and AD
- Highlights of Biomarker and Clinical Outcomes from Recent Alzheimer’s Disease Treatment Trials
- 4:15 - 4:30Break
- 4:30 - 5:30
- 5:30 - 7:30NETWORKING RECEPTION
Workshop
Alzheimeru2019s Disease Prevention Trials
Sunday, January 20, 2013 · 8:00 am - 1:30 pm
- 7:00 - 8:00 amCheck-in and Breakfast
- 8:00 am - 8:10Introduction to the Workshop
- 8:10 - 9:00 amKeynote Launching the Era of Alzheimer’s Prevention Research
9:00 - 11:15am
Challenges in Treating Preclinical Alzheimeru2019s Disease
Chair: Reisa Sperling, MDMassachusetts General Hospital and Harvard Medical School, Boston, MA
- A New Era: DIAN and the Secondary Prevention of Symptomatic Alzheimer’s Disease
- Anti-Amyloid Treatment of Asymptomatic Alzheimer’s Disease: The A4 Study
- The Role of Fluid Biomarkers in Preclinical Alzheimer’s Treatment Trials
- The Role of Amyloid Imaging in Preclinical Alzheimer’s Treatment Trials
- Addressing the Ethical Challenges of Preclinical AD Prevention Trials for the Early Alzheimers Disease Workshop
- Consent for Revealing Biomarker Status in AD Prevention Trials
- 11:15am - 11:30Break
- 11:30am - 12:30 pm
- 12:30 - 1:30 pmLUNCH
Public Forum
Alzheimeru2019s Disease Prevention Trials
Sunday, January 20, 2013 · 2:00 pm - 5:30 pm
- 2:00 - 2:10 pm
2:10 - 4:30 pm
Chair: Eric Reiman, MDBanner Alzheimer’s Institute, Phoenix, AZ
- Evaluation of Different Biomarkers Ability to Predict Cognitive Decline at Various Stages of Alzheimer's Disease
- Treating Alzheimer’s Before Symptoms Begin
- What We Know About the Genetics of Alzheimer’s Disease
- The Importance of Being Informed and Participating in Trials
- 4:30 - 5:30 pmQuestions from the Audience and Panel DiscussionPanelists: Maria Carrillo, PhD, John Morris, MD, Stephen Salloway, MD, MS, Eric Reiman, MD, Reisa Sperling, MD, Scott Roberts, PhD
Programs, recordings and slides as published at the time. Slides and recordings appear only where speakers chose to share them. Affiliations are as of 2013.